{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:01:48Z","timestamp":1784779308871,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whether sentinel lymph node biopsy (SLNB) should be performed in patients with microinvasive breast cancer (MIBC) has been a matter of debate over the last decade. MIBC has a favorable prognosis and while metastasis to the axilla is rare, it can impact treatment recommendations. In this study we evaluated clinical and histological features in both MIBC and background DCIS including ER, PR, and HER-2, number of foci of MIBC, the extent of the DCIS, nuclear grade, presence of comedo necrosis, as well as surgical procedures, adjuvant treatment and follow up to identify variables which predict disease free survival (DFS), as well as the factors which influence clinical decision making. Our study included 72 MIBC patients with a mean patient follow-up time of 55\u00a0months. Three patients with MIBC had recurrence, and two deceased, leaving five patients in total with poor long-term outcomes and a DFS rate of 93.1%. Performing mastectomy, high nuclear grade, and negativity for ER and HER-2 were found to be associated with the use of SLNB, although none of these variables were found to be associated with DFS. One positive lymph node case was discovered following SLNB in our study. This suggests the use of SLNB may provide diagnostic information to some patients, although these are the anomalies. When comparing patients who had undergone SLNB to those which had not there was no difference in DFS. Certainly, the use of SLNB in MIBC is quite the conundrum. It is important to acknowledge that surgical complications have been reported, and traditional metrics used for risk assessment in invasive breast cancer may not hold true in the setting of microinvasion.<\/jats:p>","DOI":"10.1038\/s41598-022-16521-8","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T09:02:46Z","timestamp":1658307766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Microinvasive breast cancer and the role of sentinel lymph node biopsy"],"prefix":"10.1038","volume":"12","author":[{"given":"Sean M.","family":"Hacking","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara-Lynne","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Graves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Yakirevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"issue":"8","key":"16521_CR1","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/cncr.10451","volume":"94","author":"I de Mascarel","year":"2002","unstructured":"de Mascarel, I. et al. Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 94(8), 2134\u20132142 (2002).","journal-title":"Cancer"},{"issue":"9","key":"16521_CR2","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s10434-000-0656-y","volume":"7","author":"NQ Mirza","year":"2000","unstructured":"Mirza, N. Q. et al. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol 7(9), 656\u2013664 (2000).","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"16521_CR3","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1002\/1097-0142(19910315)67:6<1498::AID-CNCR2820670606>3.0.CO;2-I","volume":"67","author":"D Rosner","year":"1991","unstructured":"Rosner, D., Lane, W. W. & Penetrante, R. Ductal carcinoma in situ with microinvasion: A curable entity using surgery alone without need for adjuvant therapy. Cancer 67(6), 1498\u20131503 (1991).","journal-title":"Cancer"},{"issue":"5","key":"16521_CR4","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/0360-3016(92)90900-3","volume":"23","author":"LJ Solin","year":"1992","unstructured":"Solin, L. J. et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int. J. Radiat. Oncol. Biol. Phys. 23(5), 961\u2013968 (1992).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"16521_CR5","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1001\/archsurg.1990.01410220082011","volume":"125","author":"JH Wong","year":"1990","unstructured":"Wong, J. H., Kopald, K. H. & Morton, D. L. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch. Surg. 125(10), 1298\u20131301 (1990).","journal-title":"Arch. Surg."},{"issue":"3","key":"16521_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1245\/s10434-012-2640-8","volume":"20","author":"DN Margalit","year":"2013","unstructured":"Margalit, D. N. et al. Microinvasive breast cancer: ER, PR, and HER-2\/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann. Surg. Oncol. 20(3), 811\u2013818 (2013).","journal-title":"Ann. Surg. Oncol."},{"issue":"12","key":"16521_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/jnci\/djv263","volume":"107","author":"M Worni","year":"2015","unstructured":"Worni, M. et al. Trends in treatment patterns and outcomes for ductal carcinoma in situ. J. Natl. Cancer Inst. 107(12), 263 (2015).","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"16521_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","volume":"121","author":"M van Seijen","year":"2019","unstructured":"van Seijen, M. et al. Ductal carcinoma in situ: To treat or not to treat, that is the question. Br. J. Cancer 121(4), 285\u2013292 (2019).","journal-title":"Br. J. Cancer"},{"key":"16521_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/1471-2407-10-557","volume":"10","author":"JH Kwon","year":"2010","unstructured":"Kwon, J. H. et al. Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 10, 557 (2010).","journal-title":"BMC Cancer"},{"issue":"1","key":"16521_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ijrobp.2010.08.027","volume":"82","author":"RR Parikh","year":"2012","unstructured":"Parikh, R. R., Haffty, B. G., Lannin, D. & Moran, M. S. Ductal carcinoma in situ with microinvasion: Prognostic implications, long-term outcomes, and role of axillary evaluation. Int. J. Radiat. Oncol. Biol. Phys. 82(1), 7\u201313 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"16521_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s10549-017-4572-2","volume":"167","author":"V Sopik","year":"2018","unstructured":"Sopik, V., Sun, P. & Narod, S. A. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Res. Treat. 167(3), 787\u2013795 (2018).","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"16521_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4048\/jbc.2018.21.2.197","volume":"21","author":"M Kim","year":"2018","unstructured":"Kim, M. et al. Microinvasive carcinoma versus ductal carcinoma in situ: A comparison of clinicopathological features and clinical outcomes. J. Breast Cancer 21(2), 197\u2013205 (2018).","journal-title":"J. Breast Cancer"},{"issue":"4","key":"16521_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/bjs.11079","volume":"106","author":"F Magnoni","year":"2019","unstructured":"Magnoni, F. et al. Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ. Br. J. Surg. 106(4), 375\u2013383 (2019).","journal-title":"Br. J. Surg."},{"issue":"11","key":"16521_CR14","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1245\/s10434-020-08606-3","volume":"27","author":"B Fan","year":"2020","unstructured":"Fan, B. et al. Role of sentinel lymph node biopsy in microinvasive breast cancer. Ann. Surg. Oncol. 27(11), 4468\u20134473 (2020).","journal-title":"Ann. Surg. Oncol."},{"issue":"11","key":"16521_CR15","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/bjc.2013.177","volume":"108","author":"MG Marmot","year":"2013","unstructured":"Marmot, M. G. et al. The benefits and harms of breast cancer screening: An independent review. Br J Cancer 108(11), 2205\u20132240 (2013).","journal-title":"Br J Cancer"},{"issue":"1","key":"16521_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/ajcp\/aqaa222","volume":"156","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Significance of HER2 in microinvasive breast carcinoma: A single academic institution experience. Am. J. Clin. Pathol. 156(1), 155\u2013165 (2021).","journal-title":"Am. J. Clin. Pathol."},{"issue":"4","key":"16521_CR17","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s13277-014-2652-z","volume":"36","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumour Biol. 36(4), 2241\u20132248 (2015).","journal-title":"Tumour Biol."},{"issue":"11","key":"16521_CR18","first-page":"300060520969304","volume":"48","author":"J Zheng","year":"2020","unstructured":"Zheng, J., Yu, J. & Zhou, T. Clinical characteristics of breast ductal carcinoma in situ with microinvasion: A narrative review. J. Int. Med. Res. 48(11), 300060520969304 (2020).","journal-title":"J. Int. Med. Res."},{"issue":"1","key":"16521_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.20892\/j.issn.2095-3941.2015.0093","volume":"13","author":"H-F Niu","year":"2016","unstructured":"Niu, H.-F. et al. Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery?. Cancer Biol. Med. 13(1), 142\u2013149 (2016).","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"16521_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5858\/133.1.31","volume":"133","author":"A Grin","year":"2009","unstructured":"Grin, A., Horne, G., Ennis, M. & O\u2019Malley, F. P. Measuring extent of ductal carcinoma in situ in breast excision specimens: A comparison of 4 methods. Arch. Pathol. Lab. Med. 133(1), 31\u201337 (2009).","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"14","key":"16521_CR21","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.7150\/jca.20871","volume":"8","author":"HM Kuerer","year":"2017","unstructured":"Kuerer, H. M. et al. DCIS margins and breast conservation: MD Anderson Cancer Center multidisciplinary practice guidelines and outcomes. J. Cancer 8(14), 2653\u20132662 (2017).","journal-title":"J. Cancer"},{"issue":"6","key":"16521_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.5858\/134.6.907","volume":"134","author":"MEH Hammond","year":"2010","unstructured":"Hammond, M. E. H. et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch. Pathol. Lab. Med. 134(6), 907\u2013922 (2010).","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"11","key":"16521_CR23","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. Arch. Pathol. Lab. Med. 142(11), 1364\u20131382 (2018).","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"16521_CR24","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejrad.2008.09.037","volume":"73","author":"CC Vieira","year":"2010","unstructured":"Vieira, C. C. et al. Microinvasive ductal carcinoma in situ: Clinical presentation, imaging features, pathologic findings, and outcome. Eur. J. Radiol. 73(1), 102\u2013107 (2010).","journal-title":"Eur. J. Radiol."},{"issue":"4","key":"16521_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1245\/ASO.2006.05.013","volume":"13","author":"LG Wilke","year":"2006","unstructured":"Wilke, L. G. et al. Surgical complications associated with sentinel lymph node biopsy: Results from a prospective international cooperative group trial. Ann. Surg. Oncol. 13(4), 491\u2013500 (2006).","journal-title":"Ann. Surg. Oncol."},{"issue":"4","key":"16521_CR26","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/bcr3239","volume":"14","author":"M Jang","year":"2012","unstructured":"Jang, M. et al. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res. 14(4), R115 (2012).","journal-title":"Breast Cancer Res."},{"issue":"12","key":"16521_CR27","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/archsurg.135.12.1469","volume":"135","author":"JA Carr","year":"2000","unstructured":"Carr, J. A. et al. The association of HER-2\/neu amplification with breast cancer recurrence. Arch. Surg. 135(12), 1469\u20131474 (2000).","journal-title":"Arch. Surg."},{"key":"16521_CR28","first-page":"2735","volume":"10","author":"J Si","year":"2020","unstructured":"Si, J. et al. Multiple microinvasion foci in ductal carcinoma in situ is associated with an increased risk of recurrence and worse survival outcome. Front. Oncol. 10, 2735 (2020).","journal-title":"Front. Oncol."},{"issue":"10","key":"16521_CR29","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1245\/s10434-014-3920-2","volume":"21","author":"CB Matsen","year":"2014","unstructured":"Matsen, C. B. et al. Extent of microinvasion in ductal carcinoma in situ is not associated with sentinel lymph node metastases. Ann. Surg. Oncol. 21(10), 3330\u20133335 (2014).","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"16521_CR30","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/diagnostics12051049","volume":"12","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Regional lymph node metastasis and axillary surgery of microinvasive breast cancer: A population-based study. Diagnostics 12(5), 1049 (2022).","journal-title":"Diagnostics"},{"issue":"52","key":"16521_CR31","doi-asserted-by":"publisher","first-page":"e23593","DOI":"10.1097\/MD.0000000000023593","volume":"99","author":"G Zhang","year":"2020","unstructured":"Zhang, G. et al. Comparison of breast ductal carcinoma in situ and ductal carcinoma in situ with microinvasion, and analysis of axillary lymph node metastasis. Medicine 99(52), e23593 (2020).","journal-title":"Medicine"},{"issue":"5","key":"16521_CR32","first-page":"2665","volume":"11","author":"T Pu","year":"2018","unstructured":"Pu, T. et al. Long term prognosis of ductal carcinoma in situ with microinvasion: A retrospective cohort study. Int J Clin Exp Pathol. 11(5), 2665\u20132674 (2018).","journal-title":"Int J Clin Exp Pathol"},{"key":"16521_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijsu.2015.05.013","volume":"19","author":"Y Li","year":"2015","unstructured":"Li, Y., Zhang, S., Wei, X. & Zhang, J. The clinical features and management of women with ductal carcinoma in situ with microinvasion: A retrospective Cohort study. Int J Surg. 19, 91\u201394 (2015).","journal-title":"Int J Surg."},{"issue":"12","key":"16521_CR34","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1016\/j.humpath.2013.07.010","volume":"44","author":"L Shatat","year":"2013","unstructured":"Shatat, L. et al. Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol. 44(12), 2684\u20132689 (2013).","journal-title":"Hum Pathol"},{"issue":"8","key":"16521_CR35","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1245\/s10434-013-2924-7","volume":"20","author":"NS Kapoor","year":"2013","unstructured":"Kapoor, N. S., Shamonki, J., Sim, M. S., Chung, C. T. & Giuliano, A. E. Impact of multifocality and lymph node metastasis on the prognosis and management of microinvasive breast cancer. Ann Surg Oncol. 20(8), 2576\u20132581 (2013).","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"16521_CR36","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1245\/s10434-012-2376-5","volume":"19","author":"JM Lyons","year":"2012","unstructured":"Lyons, J. M., Stempel, M., Van Zee, K. J., Cody, H. S. Axillary Node Staging for Microinvasive Breast Cancer: Is It Justified? Ann. Surg. Oncol. 19(11), 3416\u20133421 (2012).","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"16521_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1200\/JOP.2010.000096","volume":"7","author":"JM Pimiento","year":"2011","unstructured":"Pimiento, J. M. et al. Role of axillary staging in women diagnosed with ductal carcinoma in situ with microinvasion. J. Oncol. Pract. 7(5), 309\u2013313 (2011).","journal-title":"J. Oncol. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16521-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16521-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16521-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T04:19:44Z","timestamp":1669349984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-16521-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,20]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["16521"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-16521-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,20]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author SH is cofounder of CloudPath Diagnostics LLC, New York. Author KL, DW, MB, TG, LW, EY and YW have no competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12391"}}